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Aim: To investigate the vitamin B status, with particular focus on vitamin B6, in adults with
and without incipient nephropathy secondary to type 2 diabetes mellitus.
Methods: Plasma and/or urine concentrations of vitamins B6, B1, B12, related vitamers and
biomarkers (including total homocysteine, methylmalonic acid) were measured in
120 adults with type 2 diabetes (including 46 patients with microalbuminuria) and 52
non-diabetic control subjects.
Results: Plasma concentrations of pyridoxal 50-phosphate (PLP) were significantly lower in
patients with type 2 diabetes than in control subjects (median: 22.7 nmol/L, diabetes with
microalbuminuria; 26.8 nmol/L, diabetes without microalbuminuria; 39.5 nmol/L, non-dia-
betic control; p < 0.0001). The prevalence of low PLP (<30 nmol/L) was 63%, 58%, and 25% in
the diabetes groups with and without microalbuminuria and the control group, respectively.
Plasma levels of pyridoxine and pyridoxal were also lower ( p < 0.0001), but levels of
pyridoxamine, pyridoxamine 50-phosphate, and pyridoxic acid were higher in both groups
with diabetes compared to the control group ( p < 0.001). Thiamine deficiency was highly
prevalent in all groups, whereas low vitamin B12 and elevated methylmalonic acid were rare.
Increased levels of C-reactive protein and soluble vascular cell adhesion molecule-1 were
observed in the groups with diabetes ( p < 0.05, versus healthy control).
Conclusions: Deficiency of vitamin B6 (PLP, pyridoxine, pyridoxal) and vitamin B1 (thiamine)
was prevalent in type 2 diabetes. Incipient nephropathy was associated with more pro-
nounced alterations in vitamin B6 metabolism and stronger indications of endothelial
dysfunction and inflammation.
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High blood glucose concentration promotes a variety of
reactions, including oxidative stress and formation of advanced
glycosylated end products, which have been associated with
structural and functional changes in blood vessels that eventu-
ally cause dysfunction of several organs, especially the heart,
nerves, eyes, and kidneys [1]. Diabetic kidney disease is the most
frequent cause of renal failure and end-stage renal disease in
developed countries [2,3]. It is characterized by macroalbumi-
nuria of more than 300 mg/day, progressive decline in glomeru-
lar filtration rate (GFR), and hypertension. A considerable
number of patients newly diagnosed with type 2 diabetes
mellitus may already have developed incipient nephropathy
(microalbuminuria) due to a preceding period of undiagnosed
diabetes and impaired glucose tolerance. Among the partici-
pants of the UK Prospective Diabetes Study (UKPDS), the
prevalence of microalbuminuria was 6.5% at diagnosis of type 2
diabetes and approximately 25% ten years after the diagnosis [4].
Strict glycemic control does not always inhibit the develop-
ment of nephropathy and other secondary complications of
diabetes, whereas even with suboptimal glycemic control, some
patients with long disease duration seem not susceptible to
microvascular complications [5]. The aim to prevent or delay
the onset of microvascular complications has encouraged the
search for other factors (e.g. genetic, metabolic, or nutritional),
which may predispose to secondary vascular pathology in
diabetes mellitus. The role of vitamin B supplementation in
preventing microvascular complications of diabetes has al-
ready been a focus of research for some years. Studies on
vitamin B6 vitamers (pyridoxamine, pyridoxal 50-phosphate)
and high-dose vitamin B1 suggested inhibition of albuminuria
in diabetic animal models [6–8]. High-dose thiamine has also
proofed successful in decreasing urinary albumin excretion in
clinical type 2 diabetes [9]. A combined therapy with vitamin B1
(thiamine) and vitamin B6 (pyridoxine) in patients with type 2
diabetes and nephropathy significantly decreased glycation of
nuclear DNA in leukocytes [10]. The therapeutic benefit of
vitamin B supplementation may be achieved through correcting
diabetes-related vitamin B deficiencies, which have been
observed in experimental diabetes, especially in tissues where
vascular complications develop [11–13].
Evidence for deficiencies of vitamins B1 and B12 in both type
1 and type 2 diabetes mellitus have been described in several
recent publications [14–18]. However, data on vitamin B6
deficiency in patients with type 2 diabetes and on the vitamin
B status in diabetic nephropathy are still scarce. The current
study was performed to evaluate the vitamin B status in
patients with type 2 diabetes mellitus with and without
incipient nephropathy. The status of vitamin B6 was of
primary interest.
2. Materials and methods
2.1. Study population
Adults (18 years) with type 2 diabetes mellitus with a
duration of at least 5 years, glycated hemoglobin (HbA1c) <10%(86 mmol/mol), and a body mass index (BMI) of 19–40 kg/m2
were recruited through physicians at three general and
internal medicine practices in Germany between January
and September 2011. At the same time, healthy adults (non-
diabetic control subjects) were recruited among office work-
ers, who voluntarily provided information regarding their
health situation. For a better representation of the average
population, non-diabetic control subjects were also recruited
among their relatives and friends. Exclusion criteria were as
follows: end stage renal disease with a creatinine clearance of
less than 10 mL/min, consumption of more than 50 units of
alcohol per week, significant comorbidities, history of renal
and/or pancreatic transplant, use of vitamin B supplements
(including multivitamin preparations), and participation in an
interventional study within 30 days prior to the start of this
study. Pregnant or lactating women and women planning to
become pregnant were also not recruited. Patients with
diabetes were subdivided into two groups based on renal
function: patients with microalbuminuria (urinary albumin
excretion: 30–300 mg/mg creatinine) and patients without
microalbuminuria, i.e. normal urinary albumin excretion
(<30 mg/mg creatinine). All patients and control subjects
consumed a typical Western European diet, with no special
recommendations on food protein content. The study was
designed and performed in accordance with the ethical
principles stated in the Declaration of Helsinki and was
reviewed and approved by the Ethics Committee of the State
Chamber of Physicians of Rhineland-Palatinate, Germany. All
study participants were informed about the study purposes
and plans. Those who agreed to participate gave their written
informed consent prior to any investigation.
2.2. Blood and urine sampling
Blood and urine samples were taken in the morning after an
overnight fast. Venous blood (5 mL) was drawn from patients
with diabetes to determine fasting blood glucose (HemoCue
Glucose 201+ analyzer, HemoCue AB), HbA1c (high-perfor-
mance liquid chromatography, immunturbidimetry), and
serum creatinine (Jaffe´ photometric method). The GFR was
estimated according to the Modification of Diet in Renal Disease
formula. Micral-Test1 (Roche Diagnostics GmbH) strips were
used for semiquantitative assessment of urinary albumin
concentrations in diabetic patients. Presence of glucose and
total protein in spot urine samples of non-diabetic control
subjects were assessed by dipstick tests (Siemens Multistix 10
SG, Siemens Healthcare Diagnostics Ltd.).
Blood samples from each patient and control subject were
collected in heparinized tubes (5 mL) and in tubes without
anticoagulant (10 mL) to determine markers of vitamin B
status, lipid metabolism, and hepatic and renal function, C-
reactive protein (CRP), and soluble vascular cell adhesion
molecule-1 (sVCAM-1). Serum or plasma was separated
immediately from blood cells by centrifugation for 10 min at
2000  g at room temperature; aliquots were snap-frozen and
stored at 80 8C until analysis. Spot urine samples (5 mL) were
collected from each patient and control subject to determine
urinary concentrations of thiamine and vitamin B6 vitamers.
Urine samples were aliquoted, snap-frozen and stored at
80 8C until analysis.
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Serum total cholesterol, triglyceride, low density lipoprotein
(LDL), and high density lipoprotein (HDL) concentrations
were determined by using automated enzymatic colorimet-
ric assays; alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were determined using a standard-
ized UV kinetic method (cobas1 systems, Roche/Hitachi,
Roche Diagnostics GmbH, Mannheim, Germany). Cystatin C,
sVCAM-1, and CRP were analyzed by quantitative sandwich
enzyme immunoassays (Quantikine1, R&D Systems, Abing-
don, UK) according to the manufacturer’s instructions.
Thiamine, thiamine monophosphate (TMP), and thiamine
pyrophosphate (TPP) were determined by high-performance
liquid chromatography (HPLC, Dionex UltiMate 3000,
Thermo Scientific) with fluorimetric detection after pre-
column derivatization to the respective thiochromes by
using potassium ferricyanide under alkaline conditions [19].
Pyridoxal 50-phosphate (PLP), pyridoxamine 50-phosphate
(PMP), pyridoxine, pyridoxamine, pyridoxal, and pyridoxic
acid were determined by HPLC (Dionex UltiMate 3000,
Thermo Scientific) with fluorimetric detection after post-
column derivatization using sodium metabisulfite [20]. The
stock solutions were calibrated by spectrophotometer using
the following molar extinction coefficients (mM1 cm1):
e305 = 1.1 (PLP), e254 = 5.2 (PMP), e308 = 7.0 (pyridoxine),
e308 = 7.3 (pyridoxamine), e300 = 5.8 (pyridoxal hydrochlo-
ride), and e316 = 5.1 (pyridoxic acid). Urinary creatinine,
plasma methylmalonic acid (MMA), and plasma total
homocysteine were determined by using stable isotope
dilution analysis liquid chromatography–tandem mass
spectrometry as described elsewhere [21]. Vitamin B12
(cobalamin) was determined by using a competitive chemi-
luminiscent immunoassay (ADVIA Centaur1, Siemens
Healthcare Diagnostics Inc., Tarrytown, NY, USA) and
holotranscobalamin (holoTC) was determined by using a
microparticle enzyme immunoassay (AxSYM1, Axis-Shield
Diagnostics, Dundee, UK).
2.4. Statistical analysis
The study objectives were analyzed on a per-protocol basis in
all participants who had blood and urine samples taken and
analyzed. The variable of primary interest was the decrease in
plasma PLP levels in patients with type 2 diabetes (with and
without microalbuminuria) compared to non-diabetic control
subjects. For a statistical power of 0.90, the study group size
was determined as N = 52 for significance at the 5% level,
assuming a mean plasma PLP concentration of 35 nmol/L (SD
20%) in healthy individuals and an estimated decrease in PLP
by 20% in patients with diabetes and microalbuminuria. All
other variables were considered secondary and were analyzed
in a strictly exploratory manner. Non-parametric methods
(two-sided Wilcoxon rank sum test or Fisher’s exact test) were
used to test for differences in demographic characteristics,
vital signs at baseline, and analyte concentrations between
patients with diabetes and non-diabetic control subjects, for
differences in vitamin B12 parameters between patients with
and without metformin therapy, and for differences in PLP
levels between men and women. Pearson’s correlationanalysis was performed between PLP and age, BMI, and body
weight. Statistical analyses were performed using the soft-
ware SAS1 for Windows 9.3.1 (SAS Institute Inc., Cary, NC,
USA).
3. Results
3.1. Demographic and medical characteristics of the study
population
A total of 174 participants, i.e. patients with type 2 diabetes
mellitus with and without microalbuminuria and non-diabetic
control subjects, were enrolled in this study. Two patients
were excluded from the per-protocol analysis due to violation
of inclusion criteria. Relevant characteristics of the three
study groups are presented in Table 1. The patients with and
without microalbuminuria were similar with regard to age,
BMI, smoking history, and alcohol consumption. Control
subjects were on average younger than patients with type 2
diabetes. Only 4 patients with diabetes (3.3% of 120 patients)
were 50 years of age compared to 34 control subjects (65.4%
of 52 subjects). In addition, the majority of the patients, i.e.
103 patients with diabetes (85.8%), were overweight or obese
(BMI > 25 kg/m2) compared to 17 control subjects (32.7%).
Alcohol consumption was more frequent in the control group
than in the groups with type 2 diabetes ( p < 0.05). Diabetes
was well controlled in most patients; the mean HbA1c was
7.3% (corresponding to 65 mmol/mol) in patients with and
without microalbuminuria. Mean serum creatinine values
and mean GFR did not indicate severe or progressed kidney
disease in the patients with type 2 diabetes and microalbu-
minuria.
The most frequent comorbidities in the patients with
diabetes were hypertension and cardiovascular diseases.
Medications that may contribute to a vitamin B12 deficiency
(metformin, proton-pump inhibitors, or ACE inhibitors) were
used by 33 patients (72%) with and by 50 patients (68%) without
microalbuminuria, and by 2 control subjects (4%).
3.2. Markers of lipid metabolism, liver and kidney
function, inflammation, and endothelial dysfunction
The median serum level of total cholesterol was slightly
above normal in non-diabetic control subjects but not
significantly different compared to the groups with diabetes
( p > 0.05; Table 2). Other markers of lipid metabolism were
within normal reference ranges in all groups; however,
triglyceride levels were higher ( p < 0.0001) and HDL levels
were lower ( p < 0.0001) in the diabetes groups than in the
control group. Median ALT and AST concentrations were
indicative of normal liver function. Cystatin C, a marker of
kidney function, was significantly higher in both diabetes
groups compared to the control group ( p < 0.0001); in patients
with type 2 diabetes and microalbuminuria, median cystatin
C level was at the upper limit of the normal reference range.
Median serum levels of markers indicating inflammation
(CRP) or endothelial dysfunction (sVCAM-1) were increased
in both diabetes groups compared to the control group
( p < 0.05).
Table 1 – Characteristics of patients with type 2 diabetes with and without microalbuminuria and non-diabetic control
subjects.
Characteristic Type 2 diabetes with
MA (N = 46)
Type 2 diabetes without
MA (N = 74)
Healthy control
(N = 52)
Sex, male/female (N) 23/23 38/36 18/34
Age (years) 72 (51, 86)*** 71 (47, 83)*** 43 (19, 73)
BMI (kg/m2) 30 (21, 39)*** 29 (22, 38)*** 24 (19, 36)
Smoker, never/former/current (N) 37/7/2* 57/9/8* 42/0/10
Alcohol, none/moderate/excessivea (N) 32/14/0* 53/21/0* 22/30/0
Systolic BP (mmHg) 140 (100, 180)*** 140 (110, 180)*** 121 (100, 150)
Diastolic BP (mmHg) 80 (70, 100) 80 (60, 100)* 80 (55, 93)
Heart rate (bpm) 70 (50, 96) 70 (45, 98)* 68 (42, 92)
Fasting glucoseb (mmol/L) 8.0 (3.3, 15.0) 7.4 (3.1, 15.2) All negative
HbA1c (%) 7.3 (5.8, 9.9) 7.1 (5.5, 9.9) n.d.
Serum creatinine (mmol/L) 84.0 (53.0, 168.0) 79.6 (44.2, 159.1) n.d.
Urinary albumin/total proteinc (mg/L) 50 (30, 100) 20 (0, 20) All negative
GFR (mL/min) 69 (25, 214) 80 (39, 143) n.d.
Medication, MET/PPI/ACE (N) 17/4/20 37/3/26 0/1/1
Data are presented as median (min, max). ACE = angiotensin-converting-enzyme inhibitor; BP = blood pressure; MA = microalbuminuria;
MET = metformin; n.d. = not determined; PPI = proton-pump inhibitor.
a Excessive alcohol consumption: >50 unit/week.
b Diabetes: plasma glucose; control: glucose in urine, test considered negative below 4–7 mmol/L glucose.
c Diabetes: urinary albumin; control: urine total protein, test considered negative below 300 mg/L total protein.
* p < 0.05 versus non-diabetic control group.
*** p < 0.0001 versus non-diabetic control group.
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The median plasma or serum concentrations of vitamins B6,
B1, and B12, their respective vitamers or biomarkers are given
in Table 3. The prevalence of low plasma PLP (<30 nmol/L [22])
was 63% (N = 29) in the diabetes group with microalbuminuria,
58% (N = 43) in the diabetes group without microalbuminuria,
and 25% (N = 13) in the control group. Median plasma
concentrations of the vitamin B6 vitamers PLP, pyridoxine
and pyridoxal were significantly decreased in both diabetes
groups compared to the control group ( p < 0.0001, all
parameters); median PLP was decreased by 43% in patients
with microalbuminuria and by 32% in patients without
microalbuminuria. On the other hand, median plasma levels
of pyridoxamine, PMP, and pyridoxic acid were significantly
higher in the diabetes groups than in the control groupTable 2 – Serum biochemical parameters of lipid metabolism, 
dysfunction.
Parameter Type 2 diabetes with
MA (N = 46)
Total cholesterol (mg/dL) 193 (124, 262) 
Triglyceride (mg/dL) 146 (54, 400)***
HDL (mg/dL) 43 (12, 90)***
LDL (mg/dL)a 123.0 (63, 220) 
ALT (U/L) 13.0 (3.7, 41.0)***
AST (U/L) 23.8 (14.5, 46.0) 
Cystatin C (mg/mL) 1.09 (0.36, 2.50)***
CRP (mg/mL) 2.6 (0.1, 73.5)**
sVCAM-1 (ng/mL) 544 (187, 1546)***
Data are presented as median (min, max).
a LDL was measured in 73 diabetic patients without microalbuminuria (
* p < 0.05 versus non-diabetic control group.
** p < 0.001 versus non-diabetic control group.
*** p < 0.0001 versus non-diabetic control group.( p < 0.001). No significant correlations were found between
plasma PLP and age, BMI, or weight in patients with diabetes or
in the control group. Significantly higher plasma levels of
pyridoxine were found in men compared to women (mean:
42.1 vs. 29.7 nmol/L; p = 0.0134) in the group with diabetes and
microalbuminura. In the control group, higher urinary excre-
tion of PMP (mean: 30.1 vs. 19.8 mmol/g creatinine; p = 0.0245)
and pyridoxic acid (mean: 30.1 vs. 19.6 mmol/g creatinine;
p = 0.0218) was seen in women compared to men. Pyridoxic
acid was the major vitamin B6 metabolite excreted in urine;
the excreted amounts of other vitamin B6 vitamers were small
(see Table 4). Median urinary pyridoxic acid as a proportion of
total urinary vitamin B6 was significantly higher in patients
with diabetes (with microalbuminuria: 75%, p < 0.05; without
microalbuminuria: 77%, p < 0.0001) than in non-diabetic
control subjects (63%). Compared to the control group, medianhepatic and renal function, inflammation, and endothelial
Type 2 diabetes without
MA (N = 74)
Healthy control
(N = 52)
201 (111, 321) 206 (136, 297)
131 (42, 399)*** 95 (39, 296)
50 (20, 96)*** 61 (31, 111)
126.0 (62, 225) 128.0 (72, 207)
16.0 (5.8, 42.0)** 20.0 (9.0, 66.0)
25.0 (14.1, 90.0) 24.5 (19.0, 57.0)
0.84 (0.47, 2.59)*** 0.33 (0.17, 0.82)
1.5 (0.2, 101.5)* 0.8 (0.0, 31.7)
448 (144, 1344)* 356 (169, 729)
MA).
Table 3 – Plasma concentrations of vitamin B1 and B6, serum concentrations of vitamin B12, and plasma concentrations of
MMA and total homocysteine.
Parameter Type 2 diabetes with
MA (N = 46)
Type 2 diabetes without
MA (N = 74)
Healthy control
(N = 52)
Vitamin B6 (nmol/L)
PLP 22.7 (4.5, 206.4)*** 26.8 (1.3, 166.0)*** 39.5 (15.1, 448.5)
Pyridoxinea 6.5 (1.1, 372.4)*** 7.4 (1.3, 473.6)*** 12.4 (6.7, 33.5)
Pyridoxal 11.8 (2.7, 115.1)*** 12.4 (3.3, 46.1)*** 22.6 (11.2, 119.1)
Pyridoxamineb 1.5 (0.1, 21.9)*** 1.6 (0.4, 15.9)*** 0.8 (0.1, 80.7)
PMP 10.7 (0.9, 56.1)*** 9.6 (1.1, 42.2)*** 1.4 (0.2, 57.6)
Pyridoxic acid 33.5 (14.1, 486.9)*** 30.7 (13.3, 174.7)** 21.1 (10.1, 255.5)
Vitamin B1 (nmol/L)
Thiamine 15.4 (6.2, 83.4)*** 15.5 (8.3, 55.3)*** 10.8 (4.9, 33.9)
TMP 2.3 (0.4, 21.1)*** 3.3 (0.4, 11.8)*** 5.6 (1.1, 13.2)
TPP 8.9 (5.0, 21.2)* 8.5 (4.1, 16.1)** 6.4 (2.2, 16.8)
Vitamin B12
Total cobalamin (pmol/L) 223 (101, 553) 218 (102, 1043) 246 (71, 526)
HoloTC (pmol/L)c 67 (12, 251) 74 (8, 246) 58 (7, 280)
MMA (mmol/L) 0.25 (0.05, 1.56) 0.22 (0.02, 1.36) 0.21 (0.05, 3.33)
Total homocysteine (mmol/L) 7.1 (3.1, 14.1)** 6.4 (3.4, 13.7) 5.6 (2.4, 19.5)
Data are presented as median (min, max). MA = microalbuminuria; MMA = methylmalonic acid.
a Patients with MA: N = 45, patients without MA: N = 71.
b Patients with MA: N = 44, patients without MA: N = 66, control subjects: N = 49.
c Patients with MA: N = 44, patients without MA: N = 73.
* p < 0.05 versus control subjects.
** p < 0.001 versus control subjects.
*** p < 0.0001 versus non-diabetic control group.
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in patients with diabetes with or without microalbuminuria by
27% and 17%, respectively ( p < 0.05); and urinary PMP levels
were decreased by 82% and 71%, respectively ( p < 0.0001).
The prevalence of low plasma thiamine (<70 nmol/L [23])
was 98% in the diabetes group with microalbuminuria and
100% in the diabetes group without microalbuminuria and in
the control group. Nevertheless, the median plasma levels of
thiamine were increased by 43% in patients with microalbu-
minuria and by 44% in patients without microalbuminuria
compared to the control subjects ( p < 0.0001). Median TPP
levels were also significantly higher ( p < 0.05) while TMP levels
were significantly lower ( p < 0.0001) in both groups withTable 4 – Urinary concentrations of thiamine and B6 vitamers
Parameter Type 2 diabetes with
MA (N = 46)
Vitamin B6 (mmol/g creatinine)
PLP 0.10 (0.03, 0.38) 
Pyridoxinea 0.43 (0.01, 4.12) 
Pyridoxalb 0.38 (0.13, 1.97)*
Pyridoxaminec 0.04 (0.00, 0.75) 
PMPd 0.16 (0.01, 8.57)***
Pyridoxic acid 3.74 (2.14, 41.43) 
Vitamin B1 (mmol/g creatinine)
Thiamine 0.55 (0.21, 11.87) 
Data are presented as median (min, max). MA = microalbuminuria.
a Patients with MA: N = 45, patients without MA: N = 72, control subjects
b Patients with MA: N = 45, patients without MA: N = 72.
c Patients with MA: N = 35, patients without MA: N = 61, control subjects
d Patients with MA: N = 45, patients without MA: N = 72.
* p < 0.05 versus non-diabetic control group.
*** p < 0.0001 versus non-diabetic control group.diabetes compared to the control group. Median urinary
thiamine was lowest in patients with microalbuminuria, but
there were no significant differences between the diabetes
groups and the control group ( p > 0.05; Table 4).
The prevalence of vitamin B12 deficiency (holoTC  35 pmol/L
combined with MMA  0.30 mmol/L [24]) was 8.7% (N = 4) in
the diabetes group with microalbuminuria, 6.8% (N = 5) in the
diabetes group without microalbuminuria, and 5.8% (N = 3) in
the control group. The median serum concentrations of
vitamin B12 (cobalamin) and its active form, holoTC, were
comparable between the groups with diabetes and the control
group ( p > 0.05). Likewise, median plasma concentrations of
MMA, a marker of vitamin B12 deficiency, were similar in the normalized to urinary creatinine.
Type 2 diabetes without
MA (N = 74)
Healthy control
(N = 52)
0.08 (0.01, 0.86) 0.12 (0.02, 0.66)
0.28 (0.01, 7.20) 0.49 (0.02, 5.58)
0.43 (0.16, 2.43)* 0.52 (0.20, 5.18)
0.05 (0.00, 0.25) 0.05 (0.01, 1.89)
0.26 (0.02, 8.00)*** 0.91 (0.24, 23.17)
3.99 (2.00, 20.31) 4.02 (2.26, 60.21)
0.71 (0.18, 1.86) 0.60 (0.27, 4.06)
: N = 51.
: N = 42.
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median plasma concentration of total homocysteine was
significantly higher in diabetes patients with microalbumi-
nuria than in non-diabetic control subjects ( p < 0.001).
Metformin treatment was associated with slightly lower
( p > 0.05, all comparisons) median serum vitamin B12 and
holoTC levels in patients with microalbuminuria (metformin
vs. no metformin: 188 vs. 227 pmol/L [vitamin B12]; 62 vs.
77 pmol/L [holoTC]) and in those without microalbuminuria
(metformin vs. no metformin: 212 vs. 233 pmol/L [vitamin
B12]; 63 vs. 79 pmol/L [holoTC]). Plasma concentrations of
MMA and total homocysteine were not different ( p > 0.05)
between metformin-treated and non-treated patients.
4. Discussion
The results of our study suggest that type 2 diabetes mellitus is
associated with decreased plasma PLP concentrations and
alterations in vitamin B6 metabolism, especially in patients
with incipient nephropathy. The measured median plasma
PLP levels indicated inadequate vitamin B6 status in patients
with type 2 diabetes with and without microalbuminuria,
when applying the proposed cutoff level of 30 nmol/L for
normal vitamin B6 status [22]. Indications for lower blood PLP
concentrations in type 2 diabetes compared to non-diabetic
controls were also found in a small number of previous
studies. In patients with type 2 diabetes with and without
retinopathy (mean age: approximately 55 years), mean plasma
PLP levels were significantly lower compared to the healthy
control group [16]. In a Korean study, mean plasma PLP levels
were clinically relevantly (if not significantly) decreased in
patients (mean age: 50 years) with newly diagnosed type 2
diabetes [25]. In these studies [16,25], PLP levels were not
indicative of vitamin B6 deficiency—neither in the groups with
diabetes nor in the control groups. In our German study
population, the prevalence of PLP < 30 nmol/L was more than
twice as high among patients with type 2 diabetes than among
control subjects (i.e. 63% and 58% in the groups with and
without microalbuminuria vs. 25% in the control group). In
other studies, the prevalence of plasma PLP concentrations
below the cutoff level was lower, i.e. approximately 10% in US
patients with type 1 or type 2 diabetes and sensory
polyneuropathy (mean age: 64 years) [26], and 10% in Korean
patients with newly diagnosed type 2 diabetes [25]. In the
Korean study, the prevalence of low plasma PLP was
approximately 8% in the non-diabetic control group [25].
The more advanced state of the disease (at least a 5-year
diagnosis of type 2 diabetes) of the patients in our study may
be a possible explanation for the higher prevalence of PLP
deficiency compared to the Korean study. Plasma PLP
concentrations may be related to age and sex. A survey of
PLP status in the US population found that PLP deficiency was
more prevalent in elderly men (65 years) than in younger
men; whereas in women, PLP deficiency was most prevalent in
the 21–44 years age group [27]. Moreover, differences in dietary
habits, including protein intake [28], blood albumin levels,
smoking, alcohol consumption, use of certain drugs, or
presence of autoimmune disorders may have an influence
on the vitamin B6 status. We found no correlation betweenplasma PLP and either age, BMI, or weight and detected no
differences between men and women with regard to plasma
PLP in any of the study groups. Age and sex were not matched
between the control and the diabetes groups in the current
study. The study did not include very young participants.
Although few differences between men and women were
found in urinary vitamin B6 metabolites, we cannot rule out
the source of these differences. Protein intake may be one
factor that affects vitamin B6 requirements. However, patients
were not recommended to follow a protein-deprived diet.
Therefore, there is no reason to consider dietary protein as an
explanation for differences in vitamin B6markers between the
study groups.
Plasma PLP is a commonly used marker to evaluate vitamin
B6 status. Previous studies in diabetic patients have rarely
investigated other metabolic forms of vitamin B6. Apart from
the significantly lower PLP levels in patients with type 2
diabetes, we also observed significantly lower median levels of
pyridoxine and pyridoxal, whereas median levels of pyridox-
amine, PMP, and pyridoxic acid were significantly higher in the
groups with diabetes than in the control group. These results
indicate that there may be alterations in the vitamin B6
metabolic pathways in type 2 diabetes. The underlying
mechanisms require further investigation. One potential
reason for the higher plasma PMP level may be an enhanced
release of PMP from the liver into the blood. Or, PMP may
accumulate as a result of a decreased rate of conversion to PLP,
a reaction catalyzed by the vitamin B2 (flavin-mononucleo-
tide)-dependent pyridoxine 5-phosphate oxidase in the liver.
The same enzyme also catalyzes the conversion of pyridoxine
50-phosphate to PLP. Whether its function is affected in any
way in diabetes is speculative; further evidence is missing as
we did not determine pyridoxine 50-phosphate concentrations
in this study. Nevertheless, a decreased rate of conversion
may contribute to PLP deficiency in type 2 diabetes, indepen-
dent from dietary intake of vitamin B6. We found significantly
higher plasma levels of pyridoxic acid (the major end product
of vitamin B6 metabolism) in the patients with diabetes,
especially in the group with microalbuminuria. Increased
plasma concentrations of pyridoxic acid have previously been
found in elderly people and in patients with renal insufficiency
[29–31]. Accumulation of pyridoxic acid may be the result of
impaired renal function. However, urinary concentrations of
pyridoxic acid were not significantly different in diabetes
patients and control subjects. Increased catabolism of PLP is
another possible explanation for the accumulation of plasma
pyridoxic acid, especially in combination with a decrease in
PLP [21,29].
Possible mechanisms by which vitamin B6 deficiency may
be associated with the development of microalbuminuria and
diabetic nephropathy in type 2 diabetes are (1) a potential role
of PLP deficiency in inflammatory processes [32,33], or (2)
through increased blood homocysteine levels [34]. It has been
recognized in recent years that inflammatory processes play
an important role in the progression of diabetic nephropathy
[35,36]. CRP is a marker of inflammation and a risk predictor
for cardiovascular disease [37]. Low plasma PLP was found to
be associated with elevated CRP (independent of plasma
homocysteine) in an elderly population (Framingham Heart
Study cohort) and in nephropathy secondary to type 2 diabetes
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highest in the patients with diabetes and microalbuminuria,
which was also the group with the lowest median PLP level.
The question whether PLP deficiency directly contributes to
the inflammatory process or is a result of it remains unclear.
However, current research provides evidence that PLP
deficiency is caused by a mobilization of PLP at sites of
inflammation and by its increased utilization as a coenzyme in
inflammation-related pathways [32,39].
Total homocysteine is a proposed biomarker for cardiovas-
cular disease [40]; elevated plasma levels are associated with
inflammation and oxidative stress and thus with endothelial
dysfunction [41]. PLP, vitamin B12, and folate (vitamin B9) are
cofactors in pathways of homocysteine metabolism. Deficien-
cy of one or more of these cofactors results in accumulation of
homocysteine [42]. Increased plasma total homocysteine
levels have been observed in patients with chronic kidney
disease and were associated with nephropathy in type 2
diabetes [43–45]. In our study, median total homocysteine was
not elevated in any of the groups; in fact, the values were
rather low compared to the mean homocysteine levels
ranging between 9.0 and 15.1 mmol/L found in predominantly
middle-aged European populations [46]. Nevertheless, in our
study, median homocysteine levels were significantly higher
in the patients with diabetes and microalbuminuria than in
the control subjects. Possible explanations for the relative
increase in homocysteine in this group may include the
higher prevalence of low PLP levels or a decreased elimination
of homocysteine from the blood due to incipient renal
impairment [47]. The median GFR was slightly lower in the
patients with microalbuminuria than in the patients without
microalbuminuria. Other factors, such as folate status (not
determined in this study), age, and gender, may also have
influenced the total homocysteine level.
Elevated blood levels of total homocysteine and MMA are
sensitive indicators of vitamin B12 deficiency [48]. Median
plasma concentrations of these biomarkers did not differ
between patients with type 2 diabetes and the control
subjects. The prevalence of functional vitamin B12 deficiency
(e.g. elevated MMA and lowered holoTC) was below 10% in
both diabetes groups. In accordance with an earlier report on
patients with type 2 diabetes [18], metformin usage was not
associated with significantly higher MMA or total homocyste-
ine in the current study. However, in contrast to the study by
Obeid et al. [18], metformin treatment was associated with
only a slight decrease in plasma vitamin B12 and holoTC,
which may be explained by the small sample size or renal
insufficiency in the current study (higher creatinine and lower
GFR compared to the earlier study [18]). In contrast to our
findings, retinopathy secondary to type 2 diabetes was
associated with vitamin B12 deficiency and elevated levels of
plasma total homocysteine, but not with PLP deficiency in an
Indian study population [16]. Therefore, diabetes-related
comorbidities may affect vitamin biomarkers and add
challenge to their diagnoses.
Thiamine is another B vitamin for which low plasma
concentrations have been reported in patients with diabetes
[14,49]. Our study confirmed thiamine deficiency in patients
with type 2 diabetes, irrespective of whether incipient
nephropathy was present or not. An unexpected findingwas the even higher level of thiamine deficiency in the non-
diabetic control group, since plasma thiamine concentration
had been decreased by 75% in patients with type 2 diabetes
compared to healthy volunteers in a previous study [14].
Furthermore, vitamin B1 deficiency is a rare condition in
developed countries. Apart from unbalanced diet or certain
diseases, alcohol consumption, which was more prevalent in
the control group of this study, is usually associated with
thiamine deficiency [50]. Low plasma thiamine levels have
been linked to an increase in sVCAM-1 (a marker of endothelial
dysfunction) in patients with type 1 and type 2 diabetes [14].
Our data do not seem to indicate a direct association between
sVCAM-1 and thiamine deficiency. Compared with the non-
diabetic control, sVCAM-1 levels were significantly increased
in both diabetes groups. Moreover, the median sVCAM-1 level
in patients with microalbuminuria was above the upper limit
of the normal range, indicating endothelial damage associated
with incipient nephropathy.
In conclusion, our study showed that PLP deficiency was
prevalent in patients with type 2 diabetes, especially in
patients with incipient nephropathy characterized by micro-
albuminuria. Type 2 diabetes was also associated with other
alterations in vitamin B6 metabolism, including relative
increases in PMP and pyridoxic acid, as well as with vitamin
B1 deficiency. Markers of inflammation and endothelial
dysfunction may indicate incipient nephropathy in type 2
diabetes. The exact relationships and interactions between
vitamin B and inflammation-associated pathways are yet to be
discovered. More studies are also needed to clarify the
underlying mechanisms that cause deficiency of B vitamins
in type 2 diabetes and to evaluate potential benefits and risks
of supplementation therapy for the prevention of microvas-
cular complications secondary to diabetes.
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